Customer No. 31013

In re Application of:

Pilon, Aprile et al.

Serial No.: Filed:

09/835,784 April 13, 2001

AMENDMENTS TO THE SPECIFICATION

Please amend the specification at page 17 by replacing the first paragraph with the following replacement paragraph:

Native and recombinant human uteroglobin may be used in the present invention. In a preferred embodiment, however, recombinant human uteroglobin is employed in the methods and compositions of the invention. The recombinant form of uteroglobin preferably has substantially the same amino acid sequence as that of the native human uteroglobin protein. An amino acid sequence having "substantially the same" amino acid sequence as that of the native human protein includes recombinant human uteroglobin having at least 75% identity to the native human protein. In a preferred embodiment, recombinant human uteroglobin has at least 85% identity, and in a most preferred embodiment, recombinant human uteroglobin has at least 98% identity to the native uteroglobin, native human uteroglobin having the amino acid sequence of EICPSFQRVIETLLMDTPSSYEAAMELFSPDQDMREAGAQLKKLVDTLPQKPRESIIK LMEKIAQSSLCN (SEQ ID NO.1). In a further preferred embodiment, dimeric recombinant human uteroglobin is used in the methods and compositions of the present invention (with respect to the various forms of uteroglobin, reference is made to USSN 09/120,264).

Please amend the specification at pages 68-69 by replacing the bridging paragraph with the following replacement paragraph:

In order to verify the presence of the M-type PLA2 receptor and CD148 in various UG-responsive cells, including Hfl-1, we generated rabbit polyclonal antisera against peptides derived from them. The peptides were synthesized and rabbit antisera raised using standard methods (Research Genetics, Inc.). The peptide derived from the M-type PLA2 receptor to which antisera was raised is: QNWDTGRERTVNNQSQR (SEQ ID NO. 2). The peptide derived from the CD148 protein to which antisera was raised is NGTDGASQKTPSSTGPSP VFD (SEQ ID NO. 3). Both of these peptides produced high titre antisera within three months.